

**BRAWN**



9E34E

CIN NO.: L74899DL1985PLC022468

Date: 17.08.2021

The General Manager  
Department of Corporate Services  
BSE Limited  
Floor-25, PJ Towers,  
Dalal Street, Mumbai-400001

**BSE Scrip Code: 530207**  
**Scrip Id: BRAWN**

Sub: Submission of published results under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Dear Sir/Madam,

Please find enclosed copy of Newspaper Advertisement of Un-Audited Financial Results for the quarter (Q1) ended on 30<sup>th</sup> June, 2021 published in:

- A.) Business Standard dated 13<sup>th</sup> August, 2021 (English)  
B.) Business Standard dated 13<sup>th</sup> August, 2021 (Hindi)

This is for information and necessary action please.

Thanking you,  
Yours faithfully,  
For Brawn Biotech Limited

Priyanka Sharma  
Company Secretary and Compliance Officer  
Membership No. 50385

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)



# NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034  
Phone: 040-23547532, Email: investors@natcopharma.co.in  
CIN: L24230TG1961PLC003201, www.natcopharma.co.in

## Extract of Unaudited Consolidated Financial Results for the Quarter Ended June 30, 2021

All amounts in Indian Rupees millions					
Sl. No.	Particulars	Consolidated			
		Quarter Ended 30/06/2021 (Unaudited)	Quarter Ended 31/03/2021 Refer Note-4	Quarter Ended 30/06/2020 (Unaudited)	Year Ended 31/03/2021 (Audited)
1	Revenue from operations	4,103	3,313	5,634	20,521
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	910	707	1,581	5,795
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	910	707	1,581	5,795
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	750	530	1,228	4,409
5	Total Comprehensive income for the period attributable to owners of the parent	818	600	1,249	4,496
6	Paid-up equity share capital of Rs. 2 each	365	365	364	365
7	Other equity (Revaluation reserve Rs. Nil)				40,851
8	Earnings Per Share (in Rupees) per Rs 2/-share (non-annualised)				
1	Basic	4.11	2.91	6.74	24.20
2	Diluted	4.11	2.90	6.73	24.18

- Notes:
- Summarized Unaudited Standalone Financial Results of the Company is as under
  - The above is an extract of the detailed format of financial Results for the quarter ended 30 June 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange website: www.nseindia.com and www.bseindia.com and also on the Company's website [www.natcopharma.co.in](http://www.natcopharma.co.in).
  - The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on 12 August, 2021.
  - The figures for the quarter ended 31 March 2021 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures upto the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
  - The Board of Directors at their meeting held on 12 August, 2021 have recommended an interim dividend of Rs. 2 per equity share of Rs. 2 each.

Place: Hyderabad  
Date: 12 August, 2021

For NATCO Pharma Limited  
Sd/- V.C. Nannapaneni  
Chairman & Managing Director

## BRAWN BIOTECH LIMITED

CIN: L74899DL1985PLC022468  
REGD. OFFICE: C-64, Lajpat Nagar 1, New Delhi - 110024

## Extract of Standalone Un-Audited Financial Results for the quarter ended 30<sup>th</sup> June 2021

(Rs. In Lacs)				
Sl. No.	Particulars	Standalone		
		Quarter ended 30-06-2021	Quarter ended 30-06-2020	Year ended 31-03-2021
1	Total income from operation	112.94	743.28	3,528.48
2	Net Profit/(Loss) from ordinary activities after tax	(21.81)	(21.44)	(55.06)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	(21.81)	(21.44)	(55.06)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	(22.37)	(27.85)	(46.62)
5	Equity Share Capital	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year	-	-	-
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each) (a) Basic (Rs.) (b) Diluted (Rs.)	(0.75) (0.75)	(0.93) (0.93)	(1.55) (1.55)
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each) (a) Basic (Rs.) (b) Diluted (Rs.)	(0.75) (0.75)	(0.93) (0.93)	(1.55) (1.55)

- NOTES :
- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website ([www.bseindia.com](http://www.bseindia.com)) and on the company's website ([www.brawnbiotech.com](http://www.brawnbiotech.com)).
  - The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, intangible assets, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
  - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12-08-2021.
  - The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01<sup>st</sup> April 2017 with transition date of 01<sup>st</sup> April, 2016.
  - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
  - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited  
Sd/-  
Brij Raj Gupta  
Director  
Date : 12.08.2021  
Place : Delhi

For and on behalf of Board  
For Brawn Biotech Limited  
Sd/-  
Brij Raj Gupta  
Director  
Date : 12.08.2021  
Place : Delhi

**म.प्र. गृह निर्माण एवं अधोसंरचना विकास मण्डल**

**संशोधन सूचना**

सर्वसाधारण को सूचित किया जाता है कि दिनांक 07.08.2021 को इस समाचार पत्र में रिकत स्कूल भूखण्डों की विज्ञापित में ऑनलाइन ऑफर दिनांक 17.08.2021 तक आमंत्रित होना नुदिवश प्रकाशित हो गया है, जिसे ऑनलाइन ऑफर दिनांक **25.08.2021 तक** आमंत्रित होना पड़ा जावे।

(फरीद खान)  
संपदा अधिकारी  
प्रक्षेत्र ग्वलियर  
मो. 9827441082

Visit us: <http://www.mphousing.in>  
म.प्र. माध्यम/101621/2021

**Manaksia Steels Limited**  
AN ISO 9001 : 2015 COMPANY

Corporate Identity Number: L27101WB2001PLC138341  
Registered Office : 6, Lyons Range, Turner Morrison Building, 1st Floor, Kolkata - 700001  
E-mail: [info@manaksiasteels.com](mailto:info@manaksiasteels.com), Website: [www.manaksiasteels.com](http://www.manaksiasteels.com)  
Phone: +91-33-2231 0055 / +91-33-2231 0056

**EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021**

(₹ in Lacs)			
Particulars	Quarter Ended 30th June 2021	Year Ended 31st March 2021	Quarter Ended 30th June 2020
Total Income from Operations	13,803.17	50418.86	10,767.31
Net Profit/(Loss) before taxes	1,522.00	3440.62	185.49
Net Profit/(Loss) after taxes	1,115.01	2654.33	149.07
Total Comprehensive Income [Comprising Profit/(Loss) after tax and Other Comprehensive Income after tax]	1,389.71	3164.71	457.93
Equity Share Capital	655.34	655.34	655.34
Other Equity (excluding revaluation reserve) as shown in the audited balance sheet of previous year	-	21,626.88	-
Earnings per share (of Re 1/- each) (Not annualised): (a) Basic (₹) (b) Diluted (₹)	1.70 1.70	4.05 4.05	0.23 0.23

**Key numbers of Standalone Financial Results :** (₹ in Lacs)

Particulars	Quarter Ended 30th June 2021	Year Ended 31st March 2021	Quarter Ended 30th June 2020
Total Income from Operations	11,399.16	38796.03	7,024.25
Net Profit/(Loss) before taxes	1,399.55	2685.95	138.45
Net Profit/(Loss) after taxes	1,044.18	1968.49	102.03

Notes :

- The Financial Results of the Company for the Quarter ended 30th June, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 11th August, 2021. The Statutory Auditors of the Company have carried out Limited Review of these results.
- The Consolidated Financial Results comprise of Manaksia Steels Limited, its wholly owned subsidiary, Technomet International FZE and its step-down subsidiaries, Federated Steel Mills Limited, Far East Steel Industries Limited and Sumo Agrochem Limited.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.manaksiasteels.com](http://www.manaksiasteels.com)
- The Group is closely monitoring the impact of the pandemic on all aspect of its business. The management does not see long term risks in the Group's ability to continue as a going concern and meeting its liabilities as and when they fall due. The Management has also evaluated the recoverability of receivables and realisability of inventory on hand based on subsequent realisations and customer orders respectively. However, given the uncertainties associated with the eventual outcome, nature and duration of the pandemic, the impact may be different from that estimated as on the date of approval of these financial statements.

For and on behalf of the Board of Directors  
Manaksia Steels Limited  
Sd/-  
Varun Agrawal  
(Managing Director)  
DIN : 00441271

Place : Kolkata  
Date : 11th August, 2021

**E-AUCTION NOTICE**  
**KSS Petron Private Limited (in Liquidation)**  
**Sale of assets of the Corporate Debtor, on a Slump**  
**Sale basis under the provisions of Insolvency and Bankruptcy Code, 2016**

NOTICE is hereby given to public at large for inviting bids from interested bidders in connection with the e-Auction process to be held by the Liquidator of KSS Petron Private Limited-in liquidation ("Corporate Debtor"), for the acquisition of assets of the Corporate Debtor, on a slump sale basis as per details mentioned in the table below. The Corporate Debtor is under liquidation by virtue of the Order dated 27.12.2019 passed by the Hon'ble National Company Law Tribunal, Mumbai Bench. The registered office of the Corporate Debtor is situated at Swastik Chambers, 6th Floor, Slon Trombay Road, Chembur Mumbai-400071, Maharashtra. It is a Civil Engineering, Procurement and Construction (EPC) Company.

Asset	Manner of Sale	Date and Time of Auction	Reserve Price (INR)	EMD Amount (INR)	EOI & EMD Submission Deadline	Incremental Value (INR)
Assets of the Corporate Debtor	Slump Sale	05.10.2021 From 11:00 AM to 05:00 PM	85.65 Crore	8.5 Crore	On or before 28.08.2021	Bid increments shall be multiples of 0.85 Crore.

It is clarified that, this invitation purports to invite interested bidders and does not create any kind of binding obligation on the part of the Liquidator or the Corporate Debtor to effectuate the sale. The Liquidator reserves the right to cancel or modify the process and / or not to accept and / or disqualify any bidder without assigning any reason and without any liability. The sale of assets of the Corporate Debtor through e-Auction will be conducted strictly on "AS IS WHERE IS", "AS IS WHAT IS" and "WHATEVER THERE IS BASIS".

The e-Auction Process shall take place through an online e-Auction Agency, e-Procurement Technologies Limited via website <https://nciauction.auctiontiger.net>.

Interested applicants may refer to the Teaser & Process Document1 uploaded on website of the Corporate Debtor <http://www.ksspetron.in/liquidation.html>.

For any further information or clarification, you may please reach out to the Liquidator at 011-49121644-45 or his team member, CS Lovkesh Satra at +91 83989-94547.

For KSS Petron Private Limited  
Sd/-  
CS Vineet K Chaudhary  
Liquidator

In the matter of KSS Petron Private Limited  
IBBI Registration No.: IBBI/PA-002/IP-N00103/2017-18/10246  
liquidatorksspetron@vkcindia.com (process specific)  
lp.vineetchaudhary@gmail.com (registered with IBBI)  
Address of the Liquidator registered with IBBI:  
D-38, LGF (L/S), South Extension, Part-II, New Delhi-110049  
Date: 13.08.2021  
Place: New Delhi

**GANDHI SPECIAL TUBES LIMITED**  
CIN: L27104MH1985PLC036004  
Registered Office: 201-204, 2nd Floor, Plaza, 55 Hughes Road, Next to Dharam Palace, Mumbai 400007, Maharashtra, India  
Tel: +91-22-2363 4179 Email: [complianceofficer@gandhitubes.com](mailto:complianceofficer@gandhitubes.com), Website: [www.gandhispecialtubes.com](http://www.gandhispecialtubes.com)  
Contact Person: Mr. Jitendra Khadye (Company Secretary & Compliance Officer)

**CORRIGENDUM TO PUBLIC ANNOUNCEMENT**  
**FOR THE ATTENTION OF THE EQUITY SHAREHOLDERS / BENEFICIAL OWNERS OF EQUITY SHARES OF GANDHI SPECIAL TUBES LIMITED FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES) REGULATIONS, 2018 ("BUYBACK REGULATIONS")**

This Corrigendum to Public Announcement ("Corrigendum to PA") should be read in continuation with the Public Announcement dated Wednesday, August 11, 2021 ("PA") which was published in the Business Standard (English – All Editions), Business Standard (Hindi – All Editions) and Navshakti (Marathi – Mumbai Edition) on Thursday, August 12, 2021. Capitalised terms used but not defined in this Corrigendum to PA shall have the same meanings as ascribed in the PA, unless otherwise defined.

Record Date, for the purpose of determining the entitlement and the names of the shareholders who shall be eligible to participate in the Buyback, in terms of Regulation 9(i) of the Buyback Regulations ("Record Date"), disclosed in the PA was Friday, August 27, 2021. The shareholders are requested to note that the Record Date in the PA must be read as Tuesday, August 31, 2021.

All other contents of the PA remain unchanged. A copy of this Corrigendum to PA is available on the Company's website ([www.gandhispecialtubes.com](http://www.gandhispecialtubes.com)) and is expected to be available on the SEBI website ([www.sebi.gov.in](http://www.sebi.gov.in)) and on the websites of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) / [www.nseindia.com](http://www.nseindia.com)). As per Regulation 24(i)(a) of the Buyback Regulations, the Board of Directors of the Company, in their capacity as directors, accept full and final responsibility for the information contained in this Corrigendum to PA.

For and on behalf of the Board of Directors of  
**GANDHI SPECIAL TUBES LIMITED**  
Sd/-  
Mr. Manhar G. Gandhi  
Managing Director  
DIN: 00041190  
Place: Mumbai,  
Date: August 12, 2021

Sd/-  
Mr. Jayesh Gandhi  
Director  
DIN: 00041330

Sd/-  
Mr. Jitendra Khadye  
Company Secretary  
Membership No: 61403

# Pidilite Industries Limited



## Extract of Financial Results for the Quarter Ended 30.06.2021

(₹ In crores)									
Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30.06.2021 (Unaudited)	31.03.2021 (Unaudited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)	30.06.2021 (Unaudited)	31.03.2021 (Unaudited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	Total income from operations	1626.06	1857.01	772.39	6216.33	1936.79	2235.52	877.84	7292.71
2	Net Profit for the period (before Tax and Exceptional items)	354.83	375.87	76.93	1457.08	289.74	414.81	31.67	1526.11
3	Net Profit for the period before tax (after Exceptional items)	354.83	375.87	76.93	1456.63	289.74	411.19	31.67	1522.49
4	Net Profit for the period after tax (after Exceptional items)	288.53	276.52	56.72	1081.46	217.64	307.44	15.82	1126.13
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	287.29	273.01	53.94	1080.75	223.19	300.01	13.31	1115.27
6	Equity Share Capital	50.82	50.82	50.81	50.82	50.82	50.82	50.81	50.82
7	Reserves excluding Revaluation Reserve (as shown in the Audited Balance Sheet of the previous year)				5510.40				5542.14
8	Earnings Per Share (of ₹ 1/- each ) Basic: Diluted:	@5.68 @5.67	@5.44 @5.44	@1.12 @1.12	21.28 21.27	@4.33 @4.33	@6.03 @6.02	@0.53 @0.53	22.26 22.24

@ For the period only and not annualised.

### Notes:

- The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11<sup>th</sup> August, 2021. The full format of the Unaudited Financial Results are available on the Stock Exchange websites ([www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)) and on Company's website [www.pidilite.com](http://www.pidilite.com)

Place : Mumbai

Date : 11<sup>th</sup> August, 2021

Bharat Puri

Managing Director

Regd. Office: 7<sup>th</sup> Floor, Regent Chambers, Jamnalal Bajaj Marg, 208, Nariman Point, Mumbai - 400 021.

Tel.: 91 22 2835 7000

Fax: 91 22 2835 6007

Email: [investor.relations@pidilite.co.in](mailto:investor.relations@pidilite.co.in)


[www.pidilite.com](http://www.pidilite.com)

CIN: L24100MH1969PLC014336





## 2 कंपनी समाचार

<div><div>खबरों में रहे स्टॉक</div><div></div></div>	<div>मड़गांव डॉक शिपबिल्डर्स</div> <div><div><div><div>पहली तिमाही में शुद्ध लाभ 7 गुना बढ़ा</div><div>₹ 239.6 पिछला बंद भाव</div><div>₹ 251.6 आज का बंद भाव</div><div>▲ 5.0 %</div></div><div><div><div>25%</div><div>248</div><div>246</div><div>242</div><div>236</div></div><div><div>251.55</div><div>246.90</div><div>239.55</div></div><div><div>Aug 5</div><div>2021</div><div>Aug 11</div><div>Aug 12</div></div></div></div></div>	<div>सुंदरम फास्टेनर्स</div> <div><div><div><div>पहली तिमाही में 120 करोड़ रुपये का लाभ</div><div>₹ 739.0 पिछला बंद भाव</div><div>₹ 807.6 आज का बंद भाव</div><div>▲ 9.3 %</div></div><div><div><div>840</div><div>800</div><div>760</div><div>720</div></div><div><div>807.55</div><div>801.45</div><div>739.00</div></div><div><div>Aug 5</div><div>2021</div><div>Aug 11</div><div>Aug 12</div></div></div></div></div>	<div>भारत फोर्ज</div> <div><div><div><div>पहली तिमाही में 153 करोड़ रुपये का लाभ</div><div>₹ 783.5 पिछला बंद भाव</div><div>₹ 827.5 आज का बंद भाव</div><div>▲ 5.6 %</div></div><div><div><div>855</div><div>815</div><div>775</div><div>735</div></div><div><div>827.45</div><div>783.45</div><div>780.70</div></div><div><div>Aug 5</div><div>2021</div><div>Aug 11</div><div>Aug 12</div></div></div></div></div>	<div>यूनिकेम लैबोरेटरीज</div> <div><div><div><div>मेटफॉर्मिन हाइड्रोक्लोराइड टेबलेट के लिए यूएसएफडीए की मंजूरी</div><div>₹ 285.6 पिछला बंद भाव</div><div>₹ 300.4 आज का बंद भाव</div><div>▲ 5.2 %</div></div><div><div><div>305</div><div>295</div><div>285</div><div>275</div></div><div><div>300.40</div><div>295.00</div><div>285.60</div></div><div><div>Aug 5</div><div>2021</div><div>Aug 11</div><div>Aug 12</div></div></div></div></div>	<div>हेस्टर बायोसाइंसेज</div> <div><div><div><div>पहली तिमाही में शुद्ध लाभ 118 फीसदी बढ़ा</div><div>₹ 2,201.8 पिछला बंद भाव</div><div>₹ 2,413.6 आज का बंद भाव</div><div>▲ 9.6 %</div></div><div><div><div>2,450</div><div>2,350</div><div>2,250</div><div>2,150</div></div><div><div>2,413.60</div><div>2,359.05</div><div>2,201.75</div></div><div><div>Aug 5</div><div>2021</div><div>Aug 11</div><div>Aug 12</div></div></div></div></div>
--	--	---	--	--	--